Caspofungin is a potent antifungal inhibiting glucan synthesis in Candida species. However, caspofungin is not 100% curative in candidiasis. Therefore, we evaluated combinations of fluconazole with caspofungin for murine candidemia. We could not show any benefit of combined therapy over individual antifungal drugs.
were homogenized and serial dilutions were cultured. The Mann-Whitney test was used for comparisons of tissue burdens. Because comparisons of combination groups were made with untreated controls and with each single drug arm, we adjusted the requirement for P Յ 0.02 for significance.
In a preliminary study exploring doses of fluconazole, we found that controls had a median log count of 5.89 log CFU/ kidney and that fluconazole at 0.08 mg/kg/dose reduced the counts to 5.0 log CFU/kidney, 1.25 mg/kg reduced the count to 3.63 log CFU/kidney, and 5 mg/kg reduced the count to 2.67 log CFU/kidney. All fluconazole regimens were effective at P Ͻ 0.02. Controls for a second study evaluating caspofungin showed a median of 4.78 log CFU/kidney. Caspofungin from 0.006 mg/kg to 0.1 mg/kg reduced the median kidney burden to Ͻlog 1.3 CFU/kidney. P was Ͻ0.02 for all caspofungin doses compared with controls. Figure 1 shows the effects of fluconazole therapy alone at a very low dose of 0.06 mg/kg BID (Fig. 1A) , an intermediate dose of 1 mg/kg (Fig. 1B) , and a high dose of 5 mg/kg BID (Fig. 1C) . Fluconazole was used alone at 0.06 mg/kg BID and was combined with caspofungin at doses ranging from 0.0005 through 0.0060 mg/kg (Fig. 1A) . Caspofungin was also used alone at 0.0060 mg/kg. These doses were set just below the margin of effective therapy and were selected to show any profound additive effect which a combination might show over that of each drug alone. None of the treatment regimens significantly reduced kidney counts below those of controls at these doses.
As shown in Fig. 1B , fluconazole was given at 1 mg/kg BID and caspofungin was given at 0.313 mg/kg alone. These doses were chosen because treatment with each individual drug reduced kidney counts and because it should be possible to show either additive or antagonistic effects at intermediate doses. As expected, all treatment groups were significantly superior to controls in reducing kidney burden counts (P Յ 0.02). Caspofungin at 0.313 mg/kg was superior to fluconazole at 1 mg/kg (P ϭ 0.0006). A combination of fluconazole (1 mg/kg BID) and caspofungin (0.1 mg/kg) was not superior to fluconazole alone (P Ͼ 0.02). All other combinations, including that of fluconazole at 1 mg/kg BID and caspofungin at 0.313 mg/kg (P ϭ 0.0002) and that of fluconazole at 1 mg/kg BID and caspofungin at 1.25 mg/kg (P ϭ 0.0002), were superior to fluconazole alone. However, none of the combinations were superior to In the tissue burden study (Fig. 1C) , fluconazole was given at a high 5-mg/kg BID dose both alone and in combination with caspofungin. The high dose of fluconazole should also have allowed demonstration of either additive or antagonistic effects of combination therapy. Caspofungin was given alone at doses of 0.313 to 5 mg/kg and at these same doses in combination with fluconazole. All groups were significantly superior to controls in reducing kidney burden counts (P Յ 0.02). Caspofungin alone at all three doses and in combination with fluconazole was superior to fluconazole alone (P Յ 0.02). However, just as described above and shown in Fig. 1B , none of the combination groups were superior to caspofungin alone at the same doses used in the combinations.
Although we explored a broad range of doses, the present studies were limited by what we did not examine. Treatments with the two drugs were initiated concurrently at 1 day after infection. Thus, there was no examination of sequencing of drugs or any study of the effects of delayed treatment or host immune suppression. We studied a single fluconazole-susceptible C. albicans isolate. Mice clear antifungals at different rates than humans, and while we administered fluconazole twice daily to compensate for this, we did not explore a variety of dose intervals. Nevertheless, these studies should give some pause to those who-in an uncontrolled manner-leap from preclinical studies to routine clinical practice. Combining fluconazole and caspofungin may be advantageous. Our studies do not discourage a clinical trial in that we found no antagonism. The major disadvantage of a clinical trial appears to us to be an issue of cost, but echinocandins are also costly. The data from present studies suggest that we should consider a comparative clinical trial before accepting a presumed benefit of combined fluconazole and caspofungin therapy for candidemia. 
